Literature DB >> 10049280

Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.

J Gavaldà1, C Torres, C Tenorio, P López, M Zaragoza, J A Capdevila, B Almirante, F Ruiz, N Borrell, X Gomis, C Pigrau, F Baquero, A Pahissa.   

Abstract

The purpose of this work was to evaluate the in vitro possibilities of ampicillin-ceftriaxone combinations for 10 Enterococcus faecalis strains with high-level resistance to aminoglycosides (HLRAg) and to assess the efficacy of ampicillin plus ceftriaxone, both administered with humanlike pharmacokinetics, for the treatment of experimental endocarditis due to HLRAg E. faecalis. A reduction of 1 to 4 dilutions in MICs of ampicillin was obtained when ampicillin was combined with a fixed subinhibitory ceftriaxone concentration of 4 micrograms/ml. This potentiating effect was also observed by the double disk method with all 10 strains. Time-kill studies performed with 1 and 2 micrograms of ampicillin alone per ml or in combination with 5, 10, 20, 40, and 60 micrograms of ceftriaxone per ml showed a > or = 2 log10 reduction in CFU per milliliter with respect to ampicillin alone and to the initial inoculum for all 10 E. faecalis strains studied. This effect was obtained for seven strains with the combination of 2 micrograms of ampicillin per ml plus 10 micrograms of ceftriaxone per ml and for six strains with 5 micrograms of ceftriaxone per ml. Animals with catheter-induced endocarditis were infected intravenously with 10(8) CFU of E. faecalis V48 or 10(5) CFU of E. faecalis V45 and were treated for 3 days with humanlike pharmacokinetics of 2 g of ampicillin every 4 h, alone or combined with 2 g of ceftriaxone every 12 h. The levels in serum and the pharmacokinetic parameters of the humanlike pharmacokinetics of ampicillin or ceftriaxone in rabbits were similar to those found in humans treated with 2 g of ampicillin or ceftriaxone intravenously. Results of the therapy for experimental endocarditis caused by E. faecalis V48 or V45 showed that the residual bacterial titers in aortic valve vegetations were significantly lower in the animals treated with the combinations of ampicillin plus ceftriaxone than in those treated with ampicillin alone (P < 0.001). The combination of ampicillin and ceftriaxone showed in vitro and in vivo synergism against HLRAg E. faecalis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049280      PMCID: PMC89173     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  High-level aminoglycoside resistance among enterococci isolated from blood cultures.

Authors:  A Bartoloni; S Stefani; A Orsi; A Nicoletti; A R Difonzo; F Paradisi
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

2.  Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin.

Authors:  E Cercenado; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

3.  Prognosis of enterococcal endocarditis.

Authors:  B Almirante; M P Tornos; M Gurgui; M Pujol; J M Miró
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

4.  Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens.

Authors:  T L Hodges; S Zighelboim-Daum; G M Eliopoulos; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  High dose ampicillin for the treatment of high-level aminoglycoside resistant enterococcal endocarditis.

Authors:  B L Jones; H A Ludlam; D F Brown
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

6.  Endocarditis due to high level gentamicin resistant Enterococcus faecium.

Authors:  S S Das; J R Anderson; A A Macdonald; K W Somerville
Journal:  J Infect       Date:  1994-03       Impact factor: 6.072

7.  Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.

Authors:  M Blatter; U Fluckiger; J Entenza; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  The efficacy of teicoplanin in the treatment of endocarditis caused by gram-positive bacteria.

Authors:  E Presterl; W Graninger; A Georgopoulos
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

9.  Relapsing native-valve enterococcal endocarditis: a unique cure with oral ciprofloxacin combination drug therapy.

Authors:  H L Sacher; W C Miller; S W Landau; M L Sacher; W A Dixon; K A Dietrich
Journal:  J Clin Pharmacol       Date:  1991-08       Impact factor: 3.126

10.  Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.

Authors:  W C Hellinger; M S Rouse; P M Rabadan; N K Henry; J M Steckelberg; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

View more
  33 in total

1.  Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance.

Authors:  M C Negri; M Lipsitch; J Blázquez; B R Levin; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

Review 4.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

Review 5.  Epidemiology and antibiotic treatment of infective endocarditis: an update.

Authors:  Bruno Hoen
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

6.  Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis.

Authors:  P López; J Gavaldà; M T Martin; B Almirante; X Gomis; C Azuaje; N Borrell; L Pou; V Falcó; C Pigrau; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 7.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

8.  Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  J M Miró; C García-de-la-Mària; Y Armero; D Soy; A Moreno; A del Río; M Almela; M Sarasa; C A Mestres; J M Gatell; M T Jiménez de Anta; F Marco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

9.  Issues in the Management of Endocarditis Caused by Resistant Gram-positive Organisms.

Authors:  Martin E. Stryjewski; Vivian H. Chu; Christopher H. Cabell; Vance G. Fowler
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

10.  Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Authors:  Francesc Marco; Cristina García de la Mària; Yolanda Armero; Eurídice Amat; Dolors Soy; Asunción Moreno; Ana del Río; Manel Almela; Carlos A Mestres; José M Gatell; María Teresa Jiménez de Anta; José M Miró
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.